Atle Fund Management AB Acquires 22,033 Shares of Krystal Biotech, Inc. $KRYS

Atle Fund Management AB lifted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 109.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 42,191 shares of the company’s stock after purchasing an additional 22,033 shares during the quarter. Krystal Biotech comprises 2.9% of Atle Fund Management AB’s holdings, making the stock its 14th biggest position. Atle Fund Management AB owned approximately 0.15% of Krystal Biotech worth $7,448,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Transcend Capital Advisors LLC acquired a new position in shares of Krystal Biotech in the third quarter valued at approximately $297,000. Privium Fund Management B.V. raised its holdings in shares of Krystal Biotech by 30.6% during the third quarter. Privium Fund Management B.V. now owns 12,170 shares of the company’s stock worth $2,148,000 after acquiring an additional 2,850 shares during the period. AlphaQuest LLC lifted its position in Krystal Biotech by 14.7% in the 3rd quarter. AlphaQuest LLC now owns 664 shares of the company’s stock valued at $117,000 after acquiring an additional 85 shares in the last quarter. Arizona State Retirement System boosted its stake in Krystal Biotech by 1.3% in the 3rd quarter. Arizona State Retirement System now owns 6,397 shares of the company’s stock worth $1,129,000 after purchasing an additional 81 shares during the period. Finally, New York State Common Retirement Fund increased its holdings in Krystal Biotech by 15.4% during the 3rd quarter. New York State Common Retirement Fund now owns 26,994 shares of the company’s stock worth $4,765,000 after purchasing an additional 3,612 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Down 0.0%

NASDAQ KRYS opened at $279.24 on Friday. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $295.98. The stock has a 50 day moving average of $251.19 and a 200-day moving average of $197.11. The company has a market cap of $8.10 billion, a PE ratio of 41.87 and a beta of 0.46.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. As a group, sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of research reports. Bank of America boosted their price target on Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $310.00 target price (up previously from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the stock a “buy” rating in a research report on Friday, October 17th. Citigroup raised their price target on shares of Krystal Biotech from $320.00 to $336.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Zacks Research raised shares of Krystal Biotech from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $277.89.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider directly owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 13.70% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.